Recent trials have provided impressive clinical proofs of concept for this principle, with CD19-specific CAR-T products inducing complete clinical remission in multiple subjects with refractory Systemic Lupus Erythematosus (SLE) [3]. The gene discussed is CD19; the disease is systemic lupus erythematosus.